Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration

BOSTON and TEL-AVIV, Israel, September 28, 2023 — Quris-AI, an artificial intelligence (AI) innovator
disrupting the pharmaceutical arena, today announced the extension of its collaboration with Merck
KGaA, Darmstadt, Germany, a leading science and technology company. This follows the successful
initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison
to traditional in vitro and in vivo approaches.

Merck KGaA, Darmstadt, Germany will now further leverage Quris-AI platform’s ability to effectively
identify liver toxicity risks in a selection of drug candidates. Subsequently, Merck KGaA, Darmstadt,
Germany has the option to obtain up to a five-year exclusive license to a specific disease domain. Upon
Merck KGaA, Darmstadt, Germany exercising the option, Quris-AI may receive an undisclosed amount.

“Based on the results of our initial collaboration, we are looking forward to exploring how its BioAI
platform can advance our drug development and testing programs, and working towards an AI-enabled
IND process that reduces the reliance on animal testing,” said Danny Bar-Zohar, Global Head of Research
& Development and Chief Medical Officer for the Healthcare business sector of Merck KGaA, Darmstadt,
Germany. “If we could better focus on developing safe and effective drug candidates, we would be able
to reduce significant time and cost investments.”

The preclinical pilot study demonstrated that Quris-AI’s platform could accurately predict which drug
caused drug induced liver injury. The Quris-AI BioAI platform (29 granted and pending patents) delivers
best-in-class drug safety, through its advanced machine learning and generative AI models, which are
trained on Quris-AI’ highly predictive, proprietary data, generated from its AI-based patient-on-chip
platform. This dramatically accelerates and cuts costs of drug development, and avoids the potentially
disastrous pitfalls of traditional animal testing.

​

“The majority of drug candidates still fail once they reach clinical testing. Technology advances are
fueling a much-needed transformation in drug development,” said Dr. Isaac Bentwich, CEO of Quris-AI.
”Accurately predicting the safety of novel drugs will significantly increase the speed of drug innovation
and time to market, while substantially reducing risks and associated costs. We look forward to our
ongoing partnership with Merck KGaA, Darmstadt, Germany, as we continue to advance the field of
pharmaceutical research.”

Watch this video for perspective on how Quris-AI is reshaping the drug development process, a recent
NYSE-TV interview, or Quris-AI’s inaugural Impact Review (ESG/SDG) for more details on the company’s
global impact.

ABOUT QURIS-AI
Quris-AI, the world’s first Bio-AI clinical-prediction platform ensures the safety of new drugs.
Revolutionizing the drug development process, the company is pioneering clinical trials on chips –
testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip”. Its fully

automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster
and more cost effectively than ever before – all while minimizing animal testing. Dual-headquartered in
Boston and Israel and backed by strategic biotech and big data investors, Quris-AI is led by a proven
team of AI and medical research powerhouses. For more information, visit www.quris.ai.

​